The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Increase In Market Value Is Predicted For The Lucentis (Ranibizumab) Market During The 2026–2030 Period?
The market for lucentis (ranibizumab) has experienced substantial growth in recent years. This market is projected to expand from $3.74 million in 2025 to $3.96 million in 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. The historical growth can be attributed to clinical successes in macular degeneration treatment, an increase in diabetic retinopathy cases, an aging global population, widespread adoption by ophthalmologists, and various regulatory approvals in the eye care industry.
The lucentis (ranibizumab) market size is projected to undergo significant expansion over the next few years. It is expected to grow to $4.87 million in 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. The increase during the forecast period can be linked to the rising prevalence of retinal diseases, enhanced access to eye care services, the expansion of biosimilar competition, growing awareness of early diagnosis, and technological innovations in injection delivery. Dominant trends anticipated for the forecast period include the sustained application of anti-VEGF therapies, an increase in the treatment of retinal vascular disorders, a developing preference for intravitreal injections, the establishment of more ophthalmology specialty clinics, and a heightened emphasis on preserving vision.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19907&type=smp
What Market Drivers Are Helping Shape The Lucentis (Ranibizumab) Market Expansion?
The Lucentis (ranibizumab) market is anticipated to expand due to the increasing incidence of eye-related conditions. These disorders encompass various diseases that impact vision and compromise ocular function. The growing occurrence of these conditions stems from factors such as aging, genetic predispositions, unhealthy lifestyle choices like smoking and poor diet, and environmental influences including prolonged exposure to sunlight or digital screens. Lucentis operates by blocking vascular endothelial growth factor (VEGF), a protein known for causing irregular blood vessel formation and leakage in the retina, a primary contributor to ailments such as age-related macular degeneration (AMD) and diabetic macular edema (DME). For instance, the National Eye Institute, a US government body, projected in 2024 that 2.2 million Americans will face blindness by 2030. Consequently, the rising prevalence of eye-related disorders is a key impetus for the growth of the Lucentis (ranibizumab) market.
What Segment Types Are Included In The Lucentis (Ranibizumab) Market Analysis?
The lucentis (ranibizumab) market covered in this report is segmented –
1) By Type: Single-use Prefilled Syringe, Single-use Glass Vial
2) By Application: Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Myopic Choroidal Neovascularization, Uveitis
3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users
Which Trends Are Shaping The Lucentis (Ranibizumab) Market Landscape?
Leading companies in the Lucentis (ranibizumab) market are focusing on the development of biosimilars to present more economical alternatives to the initial branded medicine. Biosimilars are biological medical products that bear a strong resemblance to an already authorized reference biologic regarding their structure, potency, and safety, demonstrating no clinically relevant dissimilarities. For instance, in April 2024, Formycon AG, a German biotechnology enterprise, and Bioeq AG, a Swiss biotechnology enterprise, launched their biosimilar variant of Lucentis (ranibizumab), identified as FYB201, in Canada and Switzerland. Health Canada provided marketing authorization for this biosimilar, naming it Ranopto, while Swiss Medic gave its approval under the name Ranivisio. The approval and subsequent release of FYB201 aim to deliver more affordable therapeutic choices for patients grappling with retinal disorders. It functions by inhibiting vascular endothelial growth factor A (VEGF-A), a protein that stimulates abnormal blood vessel development in the retina, which can lead to swelling, fluid leakage, and a decline in vision.
Which Companies Form The Competitive Landscape Of The Lucentis (Ranibizumab) Market?
Major companies operating in the lucentis (ranibizumab) market are F.Hoffmann-La Roche Ltd, Novartis AG
Access The Complete Lucentis (Ranibizumab) Market Report:
https://www.thebusinessresearchcompany.com/report/lucentis-ranibizumab-global-market-report
Which Region Commands The Largest Share Of The Lucentis (Ranibizumab) Market?
North America was the largest region in the lucentis (ranibizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lucentis (ranibizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model